Wang, Diana G.
Barrios, Dulce M.
Blinder, Victoria S.
Bromberg, Jacqueline F.
Drullinsky, Pamela R.
Funt, Samuel A.
Jhaveri, Komal L.
Lake, Diana E.
Lyons, Tomas
Modi, Shanu
Razavi, Pedram
Sidel, Michelle
Traina, Tiffany A.
Vahdat, Linda T.
Lacouture, Mario E. http://orcid.org/0000-0002-4818-3710
Funding for this research was provided by:
National Institutes of Health (T32GM007739, P30 CA008748)
Article History
Received: 10 January 2020
Accepted: 2 June 2020
First Online: 29 June 2020
Compliance with ethical standards
:
: DGW declares no conflicts of interest. DMB declares no conflicts of interest. VSB declares consulting/advisory agreements with Pfizer and Anthem Foundation. VSB receives research funding from the NIH (5 R37 CA214785). JFB declares no conflicts of interest. PRD declares no conflicts of interest. SAF receives research funding from Genentech/Roche, AstraZeneca, and Decibel Therapeutics. SAF has stock/equity ownership in Urogen Pharma, Allogene Therapeutics, Kronos Bio, Vida Ventures, Kite Pharma, and Neogene Therapeutics. KLJ declares consulting/advisory board roles with Novartis, Spectrum Pharmaceuticals, ADC Therapeutics, Pfizer, BMS, Abbvie, AstraZeneca, Jounce Therapeutics, Taiho, Oncology, Genentech, Synthon, Lilly Pharmaceuticals, and Intellisphere. KLJ receives research funding from Novartis, Clovis Oncology, Genentech, Astra Zeneca, ADC Therapeutics, Novita Pharmaceuticals, Debio Pharmaceuticals, Pfizer, Lilly Pharmaceuticals, Zymeworks, Immunomedics, and Puma Biotechnology. DEL declares no conflicts of interest. TL declares no conflicts of interest. SM declares consulting/advisory agreements with Daiichi Sankyo, Carrick, Eli Lilly, Genentech, MacroGenics, and GSK Speakers Bureau Genetech. SM receives research support from Novartis, Genentech, Astra Zeneca/ MedImmune, Seattle Genetics, and Daiichi Sankyo. PR declares a consulting/advisory agreement with Novartis. PR receives institutional research support from Illumina and GRAIL. MS is an employee of Novartis. TAT declares consulting/advisory agreements with Genentech/Roche, Pfizer, AstraZeneca, Merck, Puma, Advaxis, Celgene, Innocrin, Genomic Health, Bristol-Myers Squibb, Samsung, Athenex, Aduro Biotech, Halozyme, Daiichi Sankyo, Ionis. TT receives research funding from Eisai, Pfizer, Novartis, Innocrin, AstraZeneca, Astellas, Immunomedics, Genentech, Daiichi, and Carrick. LTV declares no conflicts of interest. MEL declares a consulting/advisory agreement with Novartis.
: Our retrospective research study was approved by and in accordance with the ethical standards of Memorial Sloan Kettering Cancer Center’s Institutional Review Board committee (Protocol # 16-458). This article does not contain any studies with human or animals performed by any of the authors.